(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo ...

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing ...

This second lawsuit represents an escalation of Pfizer’s efforts to block the Danish drug giant’s $9bn offer for Metsera, ...

Drugmaker Pfizer on Friday sued obesity-drug developer Metsera and Novo Nordisk, seeking to block Metsera from terminating ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Pfizer has followed through on its threats, filing a lawsuit against both Metsera and Novo Nordisk during a M&A bidding war ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker's $8.5 billion bid for the U.S. obesity ...

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.